Lignox Spray

Lidocaine, the active ingredient in Lignox Spray, is a local anesthetic presented as a spray for cutaneous or oromucosal use. It provides temporary numbing of surface tissues and is used to relieve pain associated with minor skin injuries, oral lesions, and minor procedural preparations.

GNH USA supplies Lignox Spray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lignox Spray contains lidocaine, a local anesthetic that acts on peripheral nerve sodium channels to provide surface analgesia.

Minor skin abrasions, burns, or insect bites: provides temporary numbing and reduces pain during daily activities. Aphthous ulcers and other oral mucosal lesions: eases discomfort and facilitates eating or speaking. Pre‑procedural topical anesthesia for minor dermatologic or dental procedures: numbs the targeted area to improve patient tolerance.

Lignox Spray may cause local or systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient burning or stinging sensation at the application site - Mild itching or erythema of the skin or mucosa - Temporary tingling or numbness beyond the treated area

Serious or Rare Side Effects: - Allergic reactions such as angioedema, urticaria, or anaphylaxis - Systemic toxicity presenting as dizziness, seizures, or cardiac arrhythmias - Rare methemoglobinemia, especially with extensive mucosal use

When using Lignox Spray, consider the following safety measures.

Allergy assessment: avoid if known hypersensitivity to lidocaine or other amide‑type anesthetics. Application area: limit to intact skin or mucosa; do not apply to open wounds or heavily damaged tissue. Dosage limit: do not exceed the total recommended amount per treatment session as advised by the prescriber. Concurrent anesthetics: avoid using multiple lidocaine‑containing products simultaneously to prevent cumulative toxicity. Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lignox Spray may interact with other medications; consider the following.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase systemic lidocaine concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise lidocaine levels and risk toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance cardiac depressant effects of lidocaine. - Concurrent use of other local anesthetics: increases risk of cumulative systemic toxicity. - Epinephrine‑containing products: may alter lidocaine absorption and prolong its action.